Avirmax CMC Successfully Delivers First GMP Lot of AAV Vector Product for Clinical Trial Use
HAYWARD, Calif., July 17, 2024 /PRNewswire/ -- Avirmax CMC, a leader in the innovation and manufacture of adeno-associated virus (AAV) vector-mediated biotherapeutics, announces the successful delivery to its first client with Good Manufacturing Practice (GMP) lots of AAV vector product...
HAYWARD, Calif., July 17, 2024 /PRNewswire/ -- Avirmax CMC, a leader in the innovation and manufacture of adeno-associated virus (AAV) vector-mediated biotherapeutics, announces the successful delivery to its first client with Good Manufacturing Practice (GMP) lots of AAV vector product...
